Your Catalyst To a Lucrative Business
On the basis of geographies , the global autoimmune disease diagnostics market is divided into Europe , Asia Pacific , North America , and Rest of the World . In revenue terms , North America was the largest market in 2013 . This region is propelled by a well developed healthcare infrastructure and positive government initiatives , such as the Affordable Care Act and Patient Protection Act .
In terms of yearly expenditure on autoimmune disease diagnostics , North America ranks number one in the overall industry . Moreover , surging per capita spending on healthcare is projected to significantly drive regional growth till 2020 . Europe , the second largest market after North America , is propelled by technological advancements and high cases of autoimmune diseases . These technological developments are mainly observed in portable diagnostics equipment and biomarkers . Europe may derive much of its demand for autoimmune disease diagnostics from Eastern Europe .
Being a highly consolidated one , the global market for autoimmune disease diagnostics market witnesses frequent mergers & acquisitions . It is a moderately competitive industry that is led by innovations and price wars . Key competitors in the global industry are Bio Rad , Crescendo Bioscience , Roche Diagnostics , Quest Diagnostics , and Abbott Diagnostics .
In October 2016 , IQuity , a diagnostics technology company launched the IQIsolate ® technology . This technology helps identify autoimmune anomalies during its early stages . It analyzes the RNA structures in blood samples . Interestingly , IQIsolate ® has exhibited ninety percent accuracy in three key medical specialties , namely , rheumatology , gastroenterology , and neurology . The company asserts that its technology can significantly reduce the diagnostics processes of complex autoimmune diseases . It can als o differentiate between diseases that show similar symptoms . A striking feature of IQuity ’ s blood based diagnostic technology is that it helps providers & physicians confirm other types of autoimmune anomalies within a week . It is expected to gradually commercialize newer test panels that focus on rheumatology and gastroenterology .
Browse Related Category Market Reports @ https :// www . hexaresearch . com / research-category / clinicaldiagnostics-industry
Follow Us :